MX360236B - Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. - Google Patents

Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.

Info

Publication number
MX360236B
MX360236B MX2015000008A MX2015000008A MX360236B MX 360236 B MX360236 B MX 360236B MX 2015000008 A MX2015000008 A MX 2015000008A MX 2015000008 A MX2015000008 A MX 2015000008A MX 360236 B MX360236 B MX 360236B
Authority
MX
Mexico
Prior art keywords
diagnosis
keratin
prostate cancer
markers
treatment
Prior art date
Application number
MX2015000008A
Other languages
English (en)
Other versions
MX2015000008A (es
Inventor
Rajin Narain Niven
Sarangarajan Rangaprasad
K Vishnudas Vivek
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MX2015000008A publication Critical patent/MX2015000008A/es
Publication of MX360236B publication Critical patent/MX360236B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para diagnosticar cáncer de próstata en un sujeto, caracterizado porque comprende: (1) determinar un nivel de uno o más marcadores relacionados con el cáncer de próstata que comprende queratina 19 en una muestra de suero del sujeto; y (2) comparar el nivel de uno o más marcadores relacionados con el cáncer de próstata en la muestra de suero con el nivel de uno o más de los marcadores relacionados con el cáncer de próstata en una muestra de control normal, en donde el nivel incrementado de queratina 19 en la muestra de suero en relación con la muestra de control normal es indicativo de cáncer de próstata en el sujeto.
MX2015000008A 2012-06-27 2013-06-27 Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. MX360236B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261665201P 2012-06-27 2012-06-27
US201261672090P 2012-07-16 2012-07-16
US201261673094P 2012-07-18 2012-07-18
US201261702523P 2012-09-18 2012-09-18
US201261718081P 2012-10-24 2012-10-24
US201261718080P 2012-10-24 2012-10-24
US201261718064P 2012-10-24 2012-10-24
PCT/US2013/048373 WO2014004931A1 (en) 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer

Publications (2)

Publication Number Publication Date
MX2015000008A MX2015000008A (es) 2015-04-10
MX360236B true MX360236B (es) 2018-10-26

Family

ID=49783880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000008A MX360236B (es) 2012-06-27 2013-06-27 Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.

Country Status (16)

Country Link
US (3) US20140038838A1 (es)
EP (1) EP2867375B1 (es)
JP (2) JP6352909B2 (es)
KR (1) KR20150023904A (es)
CN (1) CN104583422A (es)
AU (1) AU2013284448B2 (es)
BR (1) BR112014032728A2 (es)
CA (1) CA2877721A1 (es)
EA (1) EA201492284A1 (es)
ES (1) ES2720763T3 (es)
HK (1) HK1209792A1 (es)
IL (1) IL236482A0 (es)
MX (1) MX360236B (es)
NZ (1) NZ703411A (es)
SG (1) SG11201408651TA (es)
WO (1) WO2014004931A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3102600T3 (en) * 2014-02-05 2019-04-01 Fujirebio Diagnostics Ab COMPOSITION AND PROCEDURE FOR DETECTIVE DEPARTURAL NEOPLASTIC DISEASE
SG10201808585TA (en) 2014-03-28 2018-11-29 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
KR102657306B1 (ko) 2014-12-08 2024-04-12 버그 엘엘씨 전립선암의 진단 및 치료에서 필라민을 포함하는 마커의 용도
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
KR20190034503A (ko) * 2016-06-03 2019-04-02 이투빅스 코포레이션 전립선암-연관 항원을 사용한 종양 백신접종을 위한 조성물 및 방법
US20180024132A1 (en) * 2016-07-07 2018-01-25 Berg Llc Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
WO2018189292A1 (en) * 2017-04-13 2018-10-18 Institut National De La Sante Et De La Recherche Medicale Biomarkers of castration-resistant prostatic cells
KR102405789B1 (ko) * 2018-08-24 2022-06-07 고려대학교 세종산학협력단 키누레닌 경로 대사체를 포함하는 전립선암 진단용 바이오마커 조성물
CN109608536B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用
CN109608537B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用
KR102497196B1 (ko) * 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도
CN114134223B (zh) * 2021-12-02 2022-10-11 青岛市中心血站 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942999C2 (de) 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Verfahren zum Nachweis von malignen Erkrankungen
DE4208422A1 (de) 1992-03-16 1993-09-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis von Mikrometastasen ekto- oder entodermaler Tumoren
WO1997035589A1 (en) 1996-03-26 1997-10-02 Kopreski Michael S Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein
WO1999014372A1 (en) 1997-09-15 1999-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
ATE249236T1 (de) 1998-10-22 2003-09-15 Curagen Corp Prädiktive und therapeutische für nierenerkrankungen gene und proteine
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
CA2404431C (en) 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
JP2004512029A (ja) 2000-08-16 2004-04-22 カイロン　コーポレイション ヒト遺伝子および遺伝子発現産物
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
EP1364069B1 (en) 2001-03-01 2009-04-22 Epigenomics AG Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
EP2799555B1 (en) 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2003097878A1 (fr) 2002-05-21 2003-11-27 Sysmex Corporation Amorces d'amplification d'acide nucleique destinees a detecter des cytokeratines et technique d'examen utilisant ces amorces
EP1585482A4 (en) 2002-09-25 2009-09-09 Genentech Inc NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20040109863A1 (en) * 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (de) 2002-12-19 2004-07-08 Ivonex Gmbh Trennungsverfahren
JP5479663B2 (ja) 2002-12-20 2014-04-23 セレラ コーポレーション 心筋梗塞に関連する遺伝的多型、その検出方法および使用
WO2004076614A2 (de) * 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
CA2519630A1 (en) 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
JP2007507222A (ja) 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド 化学療法に対する応答を予測するための遺伝子発現マーカー
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
ITPD20030264A1 (it) 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
CN1743849A (zh) 2004-09-03 2006-03-08 上海透景生命科技有限公司 一种多肿瘤标志物并行检测的方法及试剂盒
US20060057127A1 (en) 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en) 2004-09-17 2006-03-23 Ozge Alper Methods and compositions for diagnosing neoplastic disease
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US9234897B2 (en) 2005-03-31 2016-01-12 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
EP1883705A4 (en) 2005-05-25 2009-02-25 Expression Pathology Inc MULTIPLEX PROCESS FOR INCREASING PROTEOMIC COVERAGE FROM HISTOPATHOLOGICALLY TREATED BIOLOGICAL SAMPLES USING LIQUID TISSUE PREPARATIONS
EP1907845A4 (en) * 2005-05-25 2009-03-04 Expression Pathology Inc DIAGNOSIS OF ILLNESSES AND SUFFERING BY ANALYSIS OF HISTOPATHOLOGICALLY PREPARED BIOLOGICAL SAMPLES USING LIQUID TISSUE PREPARATIONS
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1734118A1 (en) 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
WO2007119111A2 (en) 2005-11-10 2007-10-25 Aurelium Biopharma Inc. Tissue diagnostics for ovarian cancer
WO2007071947A1 (en) * 2005-12-19 2007-06-28 University Of Hull Cancer screening test
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
JP4968577B2 (ja) 2006-04-11 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ
US20080003624A1 (en) 2006-06-13 2008-01-03 Sysmex Corporation Cancer metastasis determination method
US7901902B2 (en) 2006-07-27 2011-03-08 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US8642349B1 (en) 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
ES2375453T3 (es) 2006-09-07 2012-03-01 Universitätsklinikum Hamburg-Eppendorf Método para la detección de células epiteliales cancerosas utilizando citoqueratinas liberadas como marcadores para dichas células.
RU2473555C2 (ru) 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
CA2679664C (en) * 2007-03-02 2017-04-25 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008121307A2 (en) * 2007-03-28 2008-10-09 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090221004A1 (en) 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
EP2201134B1 (en) 2007-09-19 2018-11-21 The Research Foundation of State University of New York Gene expression signatures in enriched tumor cell samples
AU2008307579A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
MX2010004671A (es) 2007-12-10 2010-05-27 Hoffmann La Roche Seprasa como marcador para cancer.
SG10201609507TA (en) 2008-02-01 2017-01-27 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
US20110265197A1 (en) 2008-07-16 2011-10-27 Dana-Farber Cancer Institute, Inc. Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use Thereof
US9127078B2 (en) 2008-07-21 2015-09-08 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
CA2742286C (en) 2008-11-12 2016-08-09 F. Hoffmann-La Roche Ag Pacap as a marker for cancer
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
ES2490613T3 (es) 2008-12-22 2014-09-04 F. Hoffmann-La Roche Ag ARMET como marcador de cáncer
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
JP2012100536A (ja) 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
WO2010099918A1 (en) 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
WO2011040532A1 (ja) * 2009-10-02 2011-04-07 学校法人 久留米大学 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット
WO2011053837A1 (en) 2009-10-29 2011-05-05 King Kutter, Inc. Stump cutter
EP2335838B1 (en) 2009-12-18 2012-09-26 Deutsche Post AG Sorting system and method using a portable device
US20130095503A1 (en) 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
US8664472B2 (en) 2010-04-28 2014-03-04 Sesaco Corporation Pygmy sesame plants for mechanical harvesting
EP2390665A1 (en) * 2010-05-27 2011-11-30 Atlas Antibodies AB Prostate cancer biomarkers
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
CA2807811A1 (en) * 2010-07-28 2012-02-02 Metabolon Inc. Biomarkers for prostate cancer and methods using the same
US9040464B2 (en) 2010-08-16 2015-05-26 Mount Sinai Hosptial Markers of the male urogenital tract
WO2012024543A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
US9255142B2 (en) 2010-09-09 2016-02-09 Beijing Cotimes Biotech Co., Ltd. Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
US9347953B2 (en) 2010-12-06 2016-05-24 Thd S.P.A. Method for the diagnosis of a carcinoma and uses thereof
WO2012083338A1 (en) 2010-12-24 2012-06-28 Map Diagnostics Pty Ltd. Selective reaction monitoring (srm) derived protein profiles for cancer and other pathologic entities
WO2012101283A1 (en) 2011-01-28 2012-08-02 Biosystems International Sas Combinatorial biomarkers for clinical applications in lung cancer patient management
US9926601B2 (en) 2011-02-24 2018-03-27 Massachusetts Institute Of Technology Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
KR101320633B1 (ko) 2011-05-25 2013-10-30 엠앤디 (주) 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
EP2551673B1 (en) 2011-07-26 2016-01-20 Universidad de Salamanca Methods for the detection of cancer infiltration of the central nervous system
CA2844671A1 (en) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CN106526186A (zh) 2011-09-12 2017-03-22 克里蒂科斯有限责任公司 检测靶分子的非侵入性方法
WO2013134786A2 (en) 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
WO2013148316A1 (en) 2012-03-29 2013-10-03 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
TWI468519B (zh) 2012-09-05 2015-01-11 Univ China Medical Methods of detecting squamous cell carcinoma in vitro
US20150226744A1 (en) 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
US9201061B2 (en) 2013-02-26 2015-12-01 Industry-University Cooperation Foundation Hanyang University KRT19 stabilizing HER2 and use thereof
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
SE538211C2 (sv) 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav
US20150079590A1 (en) 2013-09-18 2015-03-19 Beth Israel Deaconess Medical Center, Inc. Characterization and analysis of the composition and dynamics of the mammalian riboproteome
EP3693738A1 (en) 2013-09-20 2020-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain

Also Published As

Publication number Publication date
SG11201408651TA (en) 2015-01-29
JP2015523569A (ja) 2015-08-13
US20160178632A1 (en) 2016-06-23
JP6581247B2 (ja) 2019-09-25
CA2877721A1 (en) 2014-01-03
EP2867375B1 (en) 2019-02-27
AU2013284448B2 (en) 2019-04-18
KR20150023904A (ko) 2015-03-05
MX2015000008A (es) 2015-04-10
JP6352909B2 (ja) 2018-07-04
US20180031563A1 (en) 2018-02-01
EP2867375A4 (en) 2016-06-01
BR112014032728A2 (pt) 2017-11-28
WO2014004931A1 (en) 2014-01-03
AU2013284448A1 (en) 2015-01-22
JP2018163164A (ja) 2018-10-18
IL236482A0 (en) 2015-02-26
HK1209792A1 (en) 2016-04-08
CN104583422A (zh) 2015-04-29
EA201492284A1 (ru) 2015-11-30
ES2720763T3 (es) 2019-07-24
EP2867375A1 (en) 2015-05-06
US9797905B2 (en) 2017-10-24
NZ703411A (en) 2017-09-29
US20140038838A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
AU2017225061B2 (en) Biomarkers and methods of treating PD-1 and PD-L1 related conditions
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
EP2569434A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
AU2011260390A8 (en) Means and methods for diagnosing pancreatic cancer in a subject
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
GB2538178A (en) Viscosifier polymer for treatment of a subterranean formation
NZ601065A (en) Wnt antagonists and methods of treatment and screening
WO2010017515A3 (en) Breast cancer specific markers and methods of use
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
SG10201901076WA (en) Methods of treating alzheimer's disease
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX349048B (es) Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos.
MX2016008516A (es) Metodos terapeuticos y composiciones.
MX2016001439A (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto.
EP3736022A3 (en) Treatment and diagnosis of colon cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
EP3385717A3 (en) Methods of detecting prostate cancer

Legal Events

Date Code Title Description
FG Grant or registration